Parallel administration of nanoliposomal irinotecan and levo-leucovorin for pancreatic cancer

Parallel administration of nanoliposomal irinotecan and levo-leucovorin for pancreatic cancer

Abstract Background Nanoliposomal irinotecan (nal-IRI) plus 5-fluorouracil (5-FU)/levo-leucovorin (Levo-LV) was approved for unresectable pancreatic cancer (UR-PC) in March 2020 in Japan. Levo-LV is administered by intravenous infusion over 120 min following 90 min intravenous infusion of nal-IRI (c...

Full description

Bibliographic Details
Main Authors: Ryoji Takada, Kenji Ikezawa, Takuo Yamai, Ko Watsuji, Yusuke Seiki, Yasuharu Kawamoto, Takeru Hirao, Sena Higashi, Makiko Urabe, Yugo Kai, Tasuku Nakabori, Hiroyuki Uehara, Michiyo Kotani, Toshinari Yagi, Miho Kimura, Keisuke Nozaki, Mari Takagi, Kazuyoshi Ohkawa
Format: Article
Language:English
Published: BMC 2023-07-01
Series:BMC Cancer
Subjects:
Pancreatic cancer
Nanoliposomal irinotecan
Levo-leucovorin
Chemotherapy
Online Access:https://doi.org/10.1186/s12885-023-11205-6

Internet

https://doi.org/10.1186/s12885-023-11205-6

Similar Items